Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PXMD | Common Stock | Purchase | $499K | +95K | +1.31% | $5.25* | 7.34M | Aug 30, 2022 | TardiMed Sciences, LLC | F2, F3 |
holding | PXMD | Common Stock | 361K | Aug 30, 2022 | Direct | F1 |
Id | Content |
---|---|
F1 | Includes restricted stock units that vest as described in the Company's Registration Statement on Form S-1 (File No. 333-239676). |
F2 | These shares were purchased from the underwriters by TardiMed Sciences, LLC ("TardiMed") in the issuer's initial public offering, which closed on August 30, 2022. See footnote 3 for the reporting person's relationship to TardiMed. |
F3 | The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |